Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma. Oncoimmunology 2013; 2:e26663.Soriani, A.; Fionda, C.; Ricci, B.; Iannitto, M.L.; Cippitelli, M.; Santoni, A. Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands ...
NKG2D ligands as therapeutic targets. Cancer Immun. 2013;13:8. PubMed PubMed Central Google Scholar Santos FP, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE, et al. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer. 2011;117(10...
Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma[J].Cancer gene therapy 2015,7(7).Xuan XY, Zhang JF, Hu GM, Li QR, Liu PP, Du Y. Upregulated expres- sion of NKG2D and its ligands give potential therapeutic targets for patients ...
NKG2D binds to a variety of cell surface glycoproteins distantly related to MHC class I molecules, termed NKG2D ligands (NKG2DL). NKG2DL are inducibly expressed upon cellular stress, viral infection or malignant transformation thus marking "stressed" or "harmful" cells for clearance through NKG2D ...
system, and thus this protein and its ligands are therapeutic targets for the treatment of immune diseases and cancers. Read-through transcription exists between this gene and the upstream KLRC4 (killer cell lectin-like receptor subfamily C, member 4) family member in the same cluster. [provided...
L. NKG2D ligands as therapeutic targets. Cancer Immun. 13, 8 (2013). 68. Ullrich, E., Koch, J., Cerwenka, A. & Steinle, A. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology 2, e26097 (2013). 69. VanSeggelen, H. et al. T cells engineered with chimeric ...
The immune escape mechanism of leukemic cells, including its resistance and anchorage in the bone marrow, is complex and involves many signal molecules, such as NKG2D receptor and ligands. Targeting the NKG2D/NKG2D-L axis is a promising therapeutic strategy and is therefore the focus of this ...
A various fusion protein of NKG2D is developed to be therapeutic targets in cancer research. Our proposed program will include NKG2D fusion proteins consists of Fc, monoclonal antibody, cytokine, chimeric antigen receptors. Strategy 1 Antibodies are synthesized with NKG2D to generate fusion proteins. ...
NKG2D is synthesized as a protein of 216 amino acids (aa) in length with a theoretical molecular weight of 25.3 kDa (5). The full NKG2D receptor is expressed on the cell surface as a disulfide-linked homodimer and, in humans, has several ligands expressed on tumor cells including MHC ...
Single-target CAR-T cells targeting Mesothelin (MSLN) or NKG2D ligands (NKG2DL) show good safety in clinic, but limited efficacy [5, 6]. Our analysis of TCGA [7], showed high but independent expression of MSLN and NKG2DL in TNBC tissues (Fig. S1A, S1B). Immunohistochemistry validated ...